Dr. Schwerkoske is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6025 Lake Rd
Ste 110
Woodbury, MN 55125Phone+1 651-735-7414Fax+1 651-735-1827
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1982 - 1984
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1982- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1978 - 1981
Ohio State University College of MedicineClass of 1978
Certifications & Licensure
MN State Medical License 1991 - 2025
MO State Medical License 1982 - 2024
OH State Medical License 1978 - 2024
TN State Medical License 1984 - 2024
MS State Medical License 1987 - 2023
WI State Medical License 1995 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- 155 citationsPhase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.Bret Edward Buckley Friday, S. Keith Anderson, Jan C. Buckner, Chunrong Yu, Caterina Giannini
Neuro-Oncology. 2012-02-01 - 42 citationsPhase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572David Schiff, Kurt A. Jaeckle, S. Keith Anderson, Evanthia Galanis, Caterina Giannini
Cancer. 2018-04-01 - 16 citationsPhase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.Timothy M. Kuzel, Shuli Li, John W. Eklund, Francine M. Foss, Randy D. Gascoyne
Leukemia & Lymphoma. 2007-10-13
Press Mentions
BCBS Minnesota, Minnesota Oncology Achieve 10% Cost Reduction Through Value-Based ContractDecember 23rd, 2022- Blue Cross and Blue Shield of Minnesota and Minnesota Oncology Provide Preliminary Results on Value Based AgreementDecember 16th, 2022
- Minnesota Oncology Joins Mayo Clinic Care NetworkDecember 10th, 2020
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
